Atsena Therapeutics to Present Positive Phase 1/2 Clinical Trial Data of ATSN-101 for the Treatment of GUCY2D-Associated LCA1

Atsena Therapeutics announced that positive interim data from the ongoing phase 1/2 clinical trial of ATSN-101 will be presented at the 46th Annual Macula Society Meeting, which is being held February 15-18 in Miami. This is an encore presentation of data that were presented as a late-breaker at the American Academy of Ophthalmology 2022 Annual Meeting.  

ATSN-101, Atsena’s lead investigational gene therapy product, is being evaluated in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). LCA1 is a monogenic eye disease that disrupts the function of the retina and results in early and severe vision impairment or blindness.

“Subretinal delivery of ATSN-101 was well tolerated and demonstrated clinically meaningful improvements in vision in patients treated with the highest dose," Kenji Fujita, MD, Chief Medical Officer of Atsena Therapeutics, said in a company news release. "With no approved treatments available for patients with LCA1, we are honored to be at the forefront of research for this inherited retinal disease and look forward to reporting additional data from our phase 1/2 trial at medical meetings later this year.”

Details of the presentation are as follows:

Title: Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1) 
Section: Session III - Inherited Retinal Disorders 
Date / Time: Wednesday, February 15, 6:16 p.m. EST 
Location: Fontainebleau Miami Beach   
Presenter: Christine Nichols Kay, MD, Atsena Therapeutics